AU560595B2 - Human-human hybridomas for neoplasms - Google Patents

Human-human hybridomas for neoplasms

Info

Publication number
AU560595B2
AU560595B2 AU17729/83A AU1772983A AU560595B2 AU 560595 B2 AU560595 B2 AU 560595B2 AU 17729/83 A AU17729/83 A AU 17729/83A AU 1772983 A AU1772983 A AU 1772983A AU 560595 B2 AU560595 B2 AU 560595B2
Authority
AU
Australia
Prior art keywords
human
monoclonal antibodies
cells
hybridomas
host
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
AU17729/83A
Other languages
English (en)
Other versions
AU1772983A (en
Inventor
Mark C Glassy
Hideaki Hagiwara
Yoshihide Hagiwara
Harold H. Handley
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of California
Original Assignee
University of California
University of California Berkeley
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of California, University of California Berkeley filed Critical University of California
Publication of AU1772983A publication Critical patent/AU1772983A/en
Application granted granted Critical
Publication of AU560595B2 publication Critical patent/AU560595B2/en
Anticipated expiration legal-status Critical
Expired legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Oncology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Optics & Photonics (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AU17729/83A 1982-05-21 1983-05-20 Human-human hybridomas for neoplasms Expired AU560595B2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP57-84843 1982-05-21
JP57084843A JPS58201994A (ja) 1982-05-21 1982-05-21 抗原特異的ヒト免疫グロブリンの生産方法

Publications (2)

Publication Number Publication Date
AU1772983A AU1772983A (en) 1983-12-16
AU560595B2 true AU560595B2 (en) 1987-04-09

Family

ID=13842073

Family Applications (1)

Application Number Title Priority Date Filing Date
AU17729/83A Expired AU560595B2 (en) 1982-05-21 1983-05-20 Human-human hybridomas for neoplasms

Country Status (13)

Country Link
EP (1) EP0109441B1 (enExample)
JP (2) JPS58201994A (enExample)
AT (1) ATE114189T1 (enExample)
AU (1) AU560595B2 (enExample)
CZ (1) CZ280677B6 (enExample)
DE (1) DE3382764T2 (enExample)
DK (1) DK164510C (enExample)
FI (1) FI86077C (enExample)
HU (1) HU190908B (enExample)
IN (1) IN157982B (enExample)
SK (1) SK356683A3 (enExample)
WO (1) WO1983004313A1 (enExample)
ZA (1) ZA833686B (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU589351B2 (en) * 1984-01-31 1989-10-12 Litton Bionetics, Inc. Tumor specific monoclonal antibodies

Families Citing this family (116)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1247538A (en) * 1982-05-21 1988-12-28 Mark C. Glassy Human-human hybridomas for solid tumors
US4618577A (en) * 1983-02-09 1986-10-21 The Regents Of The University Of California Human-human hybridoma, CLNH5
US4939240A (en) * 1983-03-04 1990-07-03 Health Research, Inc. Monoclonal antibodies to human breast carcinoma cells and their use in diagnosis and therapy
EP0118365B1 (en) * 1983-03-04 1990-08-29 Health Research, Inc. Monoclonal antibodies to human breast carcinoma cells and their use in diagnosis and therapy
US4613576A (en) * 1983-03-09 1986-09-23 Sloan-Kettering Institute For Cancer Research Human monoclonal antibodies to cancer cells
US4693966A (en) * 1983-03-11 1987-09-15 Sloan-Kettering Institute For Cancer Research Human monoclonal antibodies from lymphocytes of patients with malignant melanoma
GB2140030A (en) * 1983-04-08 1984-11-21 Kureha Chemical Ind Co Ltd Monoclonal antibody to human urinary bladder cancer
WO1985002411A1 (en) * 1983-11-25 1985-06-06 The University Of Melbourne Cell line and monoclonal antibody
CA1320689C (en) * 1984-03-30 1993-07-27 Alain Schreiber Monoclonal antibody specific for human basal cell surface antigen
US4886745A (en) * 1984-03-30 1989-12-12 Syntex Inc. Monoclonal antibody specific for human basal cell surface antigen
JPS6133125A (ja) * 1984-07-25 1986-02-17 Morinaga & Co Ltd ヒト単クロ−ン性抗肺ガン細胞抗体
US4761377A (en) * 1984-10-15 1988-08-02 The Regents Of The University Of California Human-human hybrid cell lines that produce antibodies against antigenic determinants on cancer cells
EP0183876A1 (en) * 1984-11-27 1986-06-11 The Board Of Trustees Of The Leland Stanford Junior University Monoclonal antibodies for endotoxin core and their use
US5106746A (en) * 1985-05-22 1992-04-21 E. I. Du Pont De Nemours And Company Process for the in vitro immunization of human splenocytes against tumor associated antigens
US5776093A (en) * 1985-07-05 1998-07-07 Immunomedics, Inc. Method for imaging and treating organs and tissues
JPH0655680B2 (ja) * 1985-10-26 1994-07-27 萩原 義秀 悪性腫瘍用ヒトモノクロナル抗体複合剤
EP0222360A3 (en) * 1985-11-12 1989-03-15 Biotherapeutics Inc. A method of producing a patient-specific cytotoxic reagent and composition
JPH0767388B2 (ja) * 1986-01-13 1995-07-26 三菱化学株式会社 抗体産生細胞株の樹立方法
WO1991009135A1 (en) * 1989-12-18 1991-06-27 Board Of Regents, The University Of Texas System Tumor-specific, cell surface-binding monoclonal antibodies
US5281710A (en) * 1990-08-01 1994-01-25 The Scripps Research Institute Dynemicin analogs: synthesis, methods of preparation and use
JPH04346792A (ja) * 1991-05-22 1992-12-02 Hagiwara Yoshihide 抗癌ヒトモノクローナル抗体のアミノ酸配列及びそれをコードするｄｎａ塩基配列
EP0528663B1 (en) * 1991-08-16 1997-10-29 Kabushiki Kaisha Toshiba Monoclonal antibody to a synaptophysin
CA2296322A1 (en) 1997-08-15 1999-02-25 Chugai Seiyaku Kabushiki Kaisha Preventives and/or remedies for systemic lupus erythematosus containing anti-il-6 receptor antibody as the active ingredient
CN1370076A (zh) 1999-08-23 2002-09-18 中外制药株式会社 Hm1.24抗原的表达增强剂
ATE498305T1 (de) 1999-10-01 2011-03-15 Chugai Pharmaceutical Co Ltd Vermeidung und behandlung von krankheiten, die mit der blutgerinnung in zusammenhang stehen
JP3986439B2 (ja) 2001-02-07 2007-10-03 中外製薬株式会社 造血器腫瘍の治療剤
UA80091C2 (en) 2001-04-02 2007-08-27 Chugai Pharmaceutical Co Ltd Remedies for infant chronic arthritis-relating diseases and still's disease which contain an interleukin-6 (il-6) antagonist
DE60334678D1 (de) 2002-02-14 2010-12-09 Chugai Pharmaceutical Co Ltd Antikörper enthaltende pharmazeutische lösungen
EP1541165A4 (en) 2002-08-27 2009-06-24 Chugai Pharmaceutical Co Ltd METHOD FOR STABILIZING PROTEIN PREPARATION
AU2003262087B2 (en) 2002-09-11 2010-11-11 Chugai Seiyaku Kabushiki Kaisha Protein purification method
GB2401040A (en) 2003-04-28 2004-11-03 Chugai Pharmaceutical Co Ltd Method for treating interleukin-6 related diseases
US7863042B2 (en) 2003-06-18 2011-01-04 Chugai Seiyaku Kabushiki Kaisha Fucose transporter
EP1652923B1 (en) 2003-08-08 2011-10-12 Perseus Proteomics Inc. Gene overexpressed in cancer
CN1914320A (zh) 2003-12-03 2007-02-14 中外制药株式会社 利用哺乳类β肌动蛋白启动子的表达体系
JPWO2005056605A1 (ja) 2003-12-12 2007-12-06 中外製薬株式会社 ３量体以上の受容体を認識する改変抗体
DE602005024502D1 (de) 2004-07-09 2010-12-16 Chugai Pharmaceutical Co Ltd Anti-glypican-3-antikörper
EP1829961A4 (en) 2004-12-22 2008-06-04 Chugai Pharmaceutical Co Ltd PROCESS FOR PREPARING ANTIBODY USING A CELL WHOSE FUCOSE CARRIER FUNCTION IS INHIBITED
EP1870459B1 (en) 2005-03-31 2016-06-29 Chugai Seiyaku Kabushiki Kaisha Methods for producing polypeptides by regulating polypeptide association
AU2006256041B2 (en) 2005-06-10 2012-03-29 Chugai Seiyaku Kabushiki Kaisha Stabilizer for protein preparation comprising meglumine and use thereof
WO2007043641A1 (ja) 2005-10-14 2007-04-19 Fukuoka University 膵島移植における移植膵島障害抑制剤
JP5398987B2 (ja) 2005-11-14 2014-01-29 セルミド リミテッド 調節性ｔ細胞の機能異常に基づく疾患の治療方法及び予防方法
AR057582A1 (es) 2005-11-15 2007-12-05 Nat Hospital Organization Agentes para suprimir la induccion de linfocitos t citotoxicos
JPWO2007061029A1 (ja) 2005-11-25 2009-05-07 学校法人慶應義塾 前立腺癌治療剤
CN104189907A (zh) 2006-01-27 2014-12-10 学校法人庆应义塾 伴有脉络膜血管生成的疾病的治疗药
EP4001409A1 (en) 2006-03-31 2022-05-25 Chugai Seiyaku Kabushiki Kaisha Methods for controlling blood pharmacokinetics of antibodies
DK2009101T3 (en) 2006-03-31 2018-01-15 Chugai Pharmaceutical Co Ltd Antibody modification method for purification of a bispecific antibody
EP2011870A4 (en) 2006-04-14 2010-09-15 Medical & Biol Lab Co Ltd MUTANT POLYPEPTIDE WITH EFFECTOR FUNCTION
RU2511406C2 (ru) 2006-06-08 2014-04-10 Чугаи Сейяку Кабусики Кайся Профилактическое или лекарственное средство для воспалительного заболевания
KR20090021217A (ko) 2006-06-14 2009-02-27 추가이 세이야쿠 가부시키가이샤 조혈 줄기세포 증가 촉진제
PE20081004A1 (es) 2006-07-13 2008-09-18 Chugai Pharmaceutical Co Ltd Agentes inductores de muerte celular
WO2008010556A1 (fr) 2006-07-21 2008-01-24 Chugai Seiyaku Kabushiki Kaisha Médicament agissant contre une maladie rénale
ATE465179T1 (de) 2006-07-24 2010-05-15 Pasteur Institut Antikörper, antikörperfragmente und scfv die an posttranslational modifizierte neurotrophine binden
WO2008020586A1 (fr) 2006-08-14 2008-02-21 Forerunner Pharma Research Co., Ltd. diagnostic et traitement du cancer à l'aide de l'anticorps anti-desmogléine-3
US20100297103A1 (en) 2006-09-14 2010-11-25 Medical & Biological Laboratories Co., Ltd. Antibody having enhanced adcc activity and method for production thereof
MY162056A (en) 2006-10-12 2017-05-31 Univ Tokyo Diagnosis and treatment of cancer using anti -ereg antibody
EP3040347A3 (en) 2006-10-20 2016-09-21 Chugai Seiyaku Kabushiki Kaisha Pharmaceutical composition comprising anti-hb-egf antibody as active ingredient
EP2123676A4 (en) 2007-01-05 2011-01-05 Univ Tokyo DIAGNOSIS AND TREATMENT OF CANCER USING ANTI-PRG-3 ANTIBODIES
JP5374360B2 (ja) 2007-02-27 2013-12-25 中外製薬株式会社 抗ｇｒｐ７８抗体を有効成分として含む医薬組成物
US8722858B2 (en) 2007-06-25 2014-05-13 Chugai Seiyaku Kabushiki Kaisha Anti-Prominin-1 antibody having ADCC activity or CDC activity
WO2009014263A1 (ja) 2007-07-26 2009-01-29 Osaka University インターロイキン６受容体阻害剤を有効成分とする眼炎症疾患治療剤
EP3127921A1 (en) 2007-09-26 2017-02-08 Chugai Seiyaku Kabushiki Kaisha Method of modifying isoelectric point of antibody via amino acid substition in cdr
CA2701155C (en) 2007-10-02 2016-11-22 Chugai Seiyaku Kabushiki Kaisha Therapeutic agents for graft-versus-host disease comprising interleukin 6 receptor inhibitor as active ingredient
JP5620106B2 (ja) 2007-10-24 2014-11-05 株式会社糖鎖工学研究所 増強されたエフェクター機能を有するポリペプチド
WO2009063970A1 (ja) 2007-11-14 2009-05-22 Forerunner Pharma Research Co., Ltd. 抗gpr49抗体を用いる癌の診断および治療
PE20091024A1 (es) 2007-11-15 2009-08-12 Chugai Pharmaceutical Co Ltd Anticuerpos monoclonales que se unen a anexelekto y sus usos
CN101939025B (zh) 2007-12-05 2015-03-25 中外制药株式会社 搔痒症治疗药
TW201634479A (zh) 2007-12-05 2016-10-01 Chugai Pharmaceutical Co Ltd 抗ｎｒ１０抗體及其應用
US20110262425A1 (en) 2007-12-12 2011-10-27 National Cancer Center Therapeutic agent for mll leukemia and moz leukemia of which molecular target is m-csf receptor, and use thereof
PE20091174A1 (es) 2007-12-27 2009-08-03 Chugai Pharmaceutical Co Ltd Formulacion liquida con contenido de alta concentracion de anticuerpo
BRPI0907237A2 (pt) 2008-01-11 2015-07-14 Univ Tokyo Anticorpo anti-cldn6
DK2275443T3 (en) 2008-04-11 2016-02-08 Chugai Pharmaceutical Co Ltd Antigen-binding molecule capable of repetitively binding to two or more antigen molecules
EP2116261A1 (en) 2008-05-07 2009-11-11 Institut Pasteur Sub-region of a plasmodium protein with improved vaccine potential and medical uses thereof
EP2283862B1 (en) 2008-06-02 2018-08-08 The University of Tokyo Combination treatment of cancer comprising anti-mfg-e8 antibody
US10717781B2 (en) 2008-06-05 2020-07-21 National Cancer Center Neuroinvasion inhibitor
CN102124030B (zh) 2008-06-20 2015-06-17 国立大学法人冈山大学 抗氧化LDL/β2GPI复合物的抗体及其用途
KR20110099762A (ko) 2008-12-26 2011-09-08 고쿠리츠다이가쿠호우진 도쿄다이가쿠 항ｌｇｒ７항체를 사용하는 암의 진단 및 치료
JP2010210772A (ja) 2009-03-13 2010-09-24 Dainippon Screen Mfg Co Ltd 液晶表示装置の製造方法
AU2010242338B2 (en) 2009-05-01 2013-12-19 Perseus Proteomics Inc. Anti-cadherin antibody
JP5808052B2 (ja) 2009-05-29 2015-11-10 中外製薬株式会社 Ｅｇｆファミリーリガンドのアンタゴニストを成分とする医薬組成物
SG178190A1 (en) 2009-07-31 2012-03-29 Shin Maeda Cancer metastasis inhibitor
TW201118166A (en) 2009-09-24 2011-06-01 Chugai Pharmaceutical Co Ltd HLA class I-recognizing antibodies
TWI505838B (zh) 2010-01-20 2015-11-01 Chugai Pharmaceutical Co Ltd Stabilized antibody solution containing
PT2535358T (pt) 2010-02-10 2018-02-23 Perseus Proteomics Inc Anticorpo anti-caderina marcado com metal radioativo
WO2011105573A1 (ja) 2010-02-26 2011-09-01 株式会社未来創薬研究所 抗icam3抗体およびその用途
TWI667346B (zh) 2010-03-30 2019-08-01 中外製藥股份有限公司 促進抗原消失之具有經修飾的FcRn親和力之抗體
HRP20221490T1 (hr) 2010-05-28 2023-02-03 Chugai Seiyaku Kabushiki Kaisha Poboljšanje antitumorskog odgovora t stanice
BR112013010136A2 (pt) 2010-10-25 2019-09-24 Univ Minnesota vacina, composição terapêutica e métodos para o tratamento ou inibição de gliblastoma
EP3404043B1 (en) 2010-10-29 2022-10-26 Perseus Proteomics Inc. Anti-cdh3 antibody having high internalization capacity
US9574005B2 (en) 2011-07-19 2017-02-21 Chugai Seiyaku Kabushiki Kaisha Stable Protein-containing preparation containing argininamide or analogous compound thereof
WO2013027802A1 (ja) 2011-08-23 2013-02-28 中外製薬株式会社 抗腫瘍活性を有する新規な抗ｄｄｒ１抗体
TW201326209A (zh) 2011-09-30 2013-07-01 Chugai Pharmaceutical Co Ltd 具有促進抗原清除之ＦｃＲｎ結合域的治療性抗原結合分子
US20140302511A1 (en) 2011-10-28 2014-10-09 Pharmalogicals Research Pte. Ltd. Cancer stem cell-specific molecule
WO2013065708A1 (ja) 2011-10-31 2013-05-10 中外製薬株式会社 重鎖と軽鎖の会合が制御された抗原結合分子
JP6113717B2 (ja) 2012-04-04 2017-04-12 株式会社ペルセウスプロテオミクス 抗ｃｄｈ３（ｐ−カドヘリン）抗体の薬剤コンジュゲート
WO2014007402A1 (ja) 2012-07-06 2014-01-09 京都府公立大学法人 眼細胞の分化マーカーおよび分化制御
JP6117222B2 (ja) 2012-09-27 2017-04-19 中外製薬株式会社 Ｆｇｆｒ３融合遺伝子およびそれを標的とする医薬
WO2014200018A1 (ja) 2013-06-11 2014-12-18 独立行政法人 国立精神・神経医療研究センター 再発寛解型多発性硬化症（ｒｒｍｓ）患者の治療予後予測方法、及び新規治療適応判断方法
TW201609093A (zh) 2013-12-27 2016-03-16 Chugai Pharmaceutical Co Ltd Ｆｇｆｒ門控蛋白變異基因及以其爲標的之醫藥
TWI787590B (zh) 2013-12-27 2022-12-21 日商中外製藥股份有限公司 等電點低之抗體的精製方法
US20170362304A1 (en) 2014-08-20 2017-12-21 Chugai Seiyaku Kabushiki Kaisha Method for measuring viscosity of protein solution
MA40764A (fr) 2014-09-26 2017-08-01 Chugai Pharmaceutical Co Ltd Agent thérapeutique induisant une cytotoxicité
AU2016224409B2 (en) 2015-02-27 2021-01-28 Chugai Seiyaku Kabushiki Kaisha Composition for treating IL-6-related diseases
AU2018240938A1 (en) 2017-03-24 2019-10-10 Zenyaku Kogyo Co., Ltd. Anti-IgM/B cell surface antigen bispecific antibody
JP7235249B2 (ja) 2017-10-20 2023-03-08 学校法人兵庫医科大学 抗ｉｌ－６受容体抗体を含有する術後の癒着を抑制するための医薬組成物
TWI822728B (zh) 2018-01-31 2023-11-21 加藤元一 含有il-6抑制劑的哮喘治療劑
CA3130909A1 (en) 2019-02-28 2020-09-03 Juntendo Educational Foundation Antibodies that bind to cleaved form of mutant calreticulin, and diagnostic, preventive, or therapeutic agent for myeloproliferative neoplasm
KR20220019670A (ko) 2019-04-17 2022-02-17 고쿠리츠다이가쿠호진 히로시마다이가쿠 Il-6 저해제 및 ccr2 저해제를 조합하여 투여하는 것을 특징으로 하는 비뇨기암의 치료제
WO2020250940A1 (ja) 2019-06-11 2020-12-17 小野薬品工業株式会社 免疫抑制剤
EP4134099A4 (en) 2020-04-06 2024-05-29 PhotoQ3 Inc. Medicine for killing tumor cells
IL300182A (en) 2020-07-28 2023-03-01 Chugai Pharmaceutical Co Ltd Preparation of a pre-filled syringe with a needle, supplied with a needle guard and containing a new modified antibody
BR112023003511A2 (pt) 2020-08-27 2023-04-11 Meiji Seika Pharma Co Ltd Anticorpo biespecífico calr-cd3 mutante anticlivado e composição farmacêutica
TW202302143A (zh) 2021-03-12 2023-01-16 日商中外製藥股份有限公司 重症肌無力症之治療或預防用之醫藥組合物
CN118043031A (zh) 2021-10-04 2024-05-14 诺华股份有限公司 表面活性剂稳定剂
IL313202A (en) 2021-12-01 2024-07-01 Chugai Pharmaceutical Co Ltd A method for preparing a formulation containing an antibody
JPWO2023163087A1 (enExample) 2022-02-25 2023-08-31
WO2025198912A1 (en) 2024-03-21 2025-09-25 Hoffmann-La Roche Inc. Methods of treating myasthenia gravis

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS57502090A (enExample) * 1980-07-18 1982-11-25
NZ198851A (en) * 1980-11-07 1984-07-31 Wistar Inst Stable,continuous human myeloma cell line capable of hybridisation with antibody-producing cells:production of hybrid cell line

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU589351B2 (en) * 1984-01-31 1989-10-12 Litton Bionetics, Inc. Tumor specific monoclonal antibodies

Also Published As

Publication number Publication date
DE3382764T2 (de) 1995-03-16
DK164510C (da) 1992-11-23
DK25084A (da) 1984-01-20
IN157982B (enExample) 1986-08-09
EP0109441B1 (en) 1994-11-17
AU1772983A (en) 1983-12-16
FI840219A0 (fi) 1984-01-19
DK164510B (da) 1992-07-06
JPH0159878B2 (enExample) 1989-12-20
EP0109441A1 (en) 1984-05-30
DK25084D0 (da) 1984-01-20
CZ280677B6 (cs) 1996-04-17
JPS60501359A (ja) 1985-08-22
HU190908B (en) 1986-12-28
DE3382764D1 (de) 1994-12-22
ATE114189T1 (de) 1994-12-15
ZA833686B (en) 1984-09-26
EP0109441A4 (en) 1986-09-22
FI86077B (fi) 1992-03-31
CZ356683A3 (en) 1995-11-15
SK279249B6 (sk) 1998-08-05
JPS58201994A (ja) 1983-11-25
FI86077C (fi) 1992-07-10
SK356683A3 (en) 1998-08-05
FI840219L (fi) 1984-01-19
WO1983004313A1 (en) 1983-12-08

Similar Documents

Publication Publication Date Title
AU560595B2 (en) Human-human hybridomas for neoplasms
US4618577A (en) Human-human hybridoma, CLNH5
Epstein et al. Two new monoclonal antibodies (LN-1, LN-2) reactive in B5 formalin-fixed, paraffin-embedded tissues with follicular center and mantle zone human B lymphocytes and derived tumors.
US5185432A (en) Monoclonal antibodies and antigen for human non-small cell lung carcinoma and other certain human carcinomas
CA1242401A (en) Human monoclonal antibodies to cancer cells
EP1064551A1 (en) Development of human monoclonal antibodies and uses thereof
CA1247538A (en) Human-human hybridomas for solid tumors
EP0232871A2 (en) Human monoclonal antibody, hybridoma producing the same and its use
WO1986007089A1 (en) Murine hybridoma lym-2 and diagnostic antibody produced thereby
US5286647A (en) Human-human hybridomas for neoplasms
JPS59137497A (ja) 抗原特異的免疫グロブリン生産性ヒト／ヒトハイブリド−マ及びその生産する抗体
EP0203552B1 (en) Monoclonal antibodies for human non-small cell lung carcinomas
Dan et al. Human antiglioma monoclonal antibodies from patients with astrocytic tumors
NO165510B (no) Monoklonale antistoffer, samt anvendelse av dem in vitro for bestemmelse av naervaer av neoplasmer.
Hadas et al. Identification of a surface antigen, common to murine lung and Lewis lung carcinoma, by monoclonal antibody
JP2626979B2 (ja) ヒト癌細胞に対するモノクロナール抗体４ｃ１および該抗体を産生するハイブリドーマ
EP0347230A2 (en) Miniclones
Banerjee et al. Human monoclonal antibodies to neuroendocrine granules derived from tumor-infiltrating lymphocytes isolated from a primitive neuroectodermal tumor
JPH01243986A (ja) 抗ヒト固形癌ヒトモノクローナル抗体，抗体産生ハイブリドーマおよび抗体の製造法
EP0285052A2 (en) Monoclonal antibody
JPH0488998A (ja) 腫瘍特異的ヒト型モノクローナル抗体

Legal Events

Date Code Title Description
MK14 Patent ceased section 143(a) (annual fees not paid) or expired